Analyzing Eagle Pharmaceuticals (NASDAQ:EGRX) and Avenue Therapeutics (NASDAQ:ATXI)

Earnings & Valuation

This table compares Avenue Therapeutics and Eagle Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avenue Therapeutics	N/A	N/A	-$10.38 million	$0.76	0.20
Eagle Pharmaceuticals	$257.55 million	0.01	$35.64 million	$1.18	0.17

Eagle Pharmaceuticals has higher revenue and earnings than Avenue Therapeutics. Eagle Pharmaceuticals is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

17.3% of Avenue Therapeutics shares are held by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are held by institutional investors. 8.6% of Avenue Therapeutics shares are held by company insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Avenue Therapeutics and Eagle Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Avenue Therapeutics	N/A	-471.57%	-296.50%
Eagle Pharmaceuticals	N/A	N/A	N/A

Volatility & Risk

Avenue Therapeutics has a beta of -0.51, meaning that its stock price is 151% less volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.

Summary

Eagle Pharmaceuticals beats Avenue Therapeutics on 9 of the 9 factors compared between the two stocks.

About Avenue Therapeutics

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.